```html

Zollinger‑Ellison Carcinoma (Gastric) – A Patient‑Friendly Guide

Overview

Zollinger‑Ellison carcinoma (sometimes called gastric Zollinger‑Ellison syndrome when the tumor is located in the stomach) is a rare, malignant neuroendocrine tumor that originates from the G‑cells of the gastric mucosa. These cells normally produce gastrin, a hormone that stimulates stomach acid secretion. When the tumor becomes cancerous, it produces excessive gastrin, leading to severe, refractory peptic ulcer disease and a characteristic constellation of symptoms.

• Incidence: Gastric neuroendocrine carcinomas account for < 1 % of all gastric cancers; Zollinger‑Ellison carcinoma is an even smaller subset—estimated at 0.2–0.5 % of all gastro‑pancreatic neuroendocrine tumors (NETs) <sup>1</sup>.
• Age & gender: Most cases are diagnosed between ages 30‑60, with a slight male predominance (≈55 %).
• Geography: No clear regional pattern, though higher rates are reported in countries with robust NET registries (U.S., Europe, Japan).

Symptoms

The tumor’s hallmark is hypergastrinemia, which drives excessive gastric acid. Symptoms often start subtly and progress rapidly.

• Refractory peptic ulcers – ulcers that recur despite standard treatment; often multiple and located in atypical sites (duodenum, jejunum).
• Abdominal pain – burning or gnawing pain, usually epigastric, worsening after meals.
• Diarrhea or watery stools – caused by acid‑induced injury to the small‑bowel mucosa.
• Heartburn / gastro‑esophageal reflux disease (GERD) – persistent burning sensation.
• Weight loss – due to malabsorption and decreased appetite.
• Nausea & vomiting – especially after large meals.
• Gastrointestinal bleeding – melena or hematemesis from ulcer erosion.
• Fatigue & anemia – secondary to chronic blood loss.
• Abdominal mass – palpable in advanced disease.
• Symptoms of metastasis – liver pain, bone pain, or respiratory symptoms if cancer spreads.

Because many of these signs overlap with common ulcer disease, a high index of suspicion is essential, especially when ulcers are “tough” to heal.

Causes and Risk Factors

Underlying mechanisms

Zollinger‑Ellison carcinoma arises from somatic mutations that transform normal gastrin‑producing neuroendocrine cells into malignant ones. Key molecular pathways include:

• MEN1 gene loss – Germline mutations cause Multiple Endocrine Neoplasia type 1 (MEN1), predisposing to gastrin‑producing tumors.
• CDKN1B (p27) alterations – Cell‑cycle dysregulation.
• Chromosome 11q13 amplification – Increases cyclin D1 expression.

Risk factors

• Family history of MEN1 or other endocrine neoplasias.
• Chronic atrophic gastritis or intestinal metaplasia – creates a proliferative environment.
• Helicobacter pylori infection – may increase gastrin levels, though a direct causative link is uncertain.
• Long‑term use of proton pump inhibitors (PPIs) – can raise gastrin modestly; however, data do not suggest PPIs cause cancer, only that they may mask early symptoms.
• Exposure to radiation or certain chemicals (e.g., nitrosamines) – theoretical risk, not well quantified.

Diagnosis

Accurate diagnosis hinges on biochemical, imaging, and histologic data.

1. Biochemical testing

• Fasting serum gastrin: Levels > 1,000 pg/mL (normal < 100 pg/mL) are strongly suggestive, especially after a calcium infusion (secretin stimulation test).
• Secretin stimulation test: Paradoxical rise in gastrin after IV secretin confirms a gastrin‑producing tumor.
• Chromogranin A (CgA): Elevated in most NETs; useful for monitoring.

2. Endoscopic evaluation

• Upper endoscopy (EGD): Visualizes ulcerations, obtains biopsies, and can detect submucosal masses.
• Endoscopic ultrasound (EUS): Provides high‑resolution images of the gastric wall and surrounding lymph nodes; allows fine‑needle aspiration for pathology.

3. Radiologic imaging

• Multiphasic CT or MRI of abdomen: Identifies primary tumor size, local invasion, and distant metastases.
• Somatostatin receptor scintigraphy (OctreoScan) or ^68Ga‑DOTATATE PET/CT: Detects somatostatin‑receptor–positive lesions; the latter offers superior sensitivity.

4. Histopathology

Biopsy specimens show neuroendocrine carcinoma features:

• Sheets of small to medium‑sized cells with scant cytoplasm.
• High mitotic rate (≥20/10 HPF) and Ki‑67 proliferation index > 20 % (classifies it as a high‑grade NET, WHO grade 3).
• Positive immunostaining for gastrin, chromogranin A, and synaptophysin.

Staging

Staging follows the AJCC 8th edition for gastric neuroendocrine carcinoma (TNM system). Accurate staging guides treatment intensity.

Treatment Options

Management is multidisciplinary: surgery, systemic therapy, acid suppression, and supportive care.

1. Acid‑suppression therapy (initial step)

• High‑dose proton pump inhibitors (PPIs): 80–120 mg daily (e.g., omeprazole 40 mg BID) to control acid‑related symptoms and prevent ulcer complications.
• H2‑receptor antagonists: Add if PPI alone is insufficient.

2. Surgical resection

• Curative intent: Partial or total gastrectomy with regional lymphadenectomy when the tumor is localized.
• En bloc resection: May include parts of the pancreas or duodenum if invasion occurs.
• Minimally invasive (laparoscopic) approaches are increasingly used for early‑stage disease.

3. Systemic therapy

• Chemotherapy: Platinum‑based regimens (cisplatin or carboplatin) combined with etoposide or irinotecan are standard for high‑grade gastric NETs.
• Targeted therapy:
  • Everolimus (mTOR inhibitor) – FDA‑approved for advanced pancreatic NETs; off‑label data suggest benefit in gastric NETs.
  • Sunitinib – Tyrosine‑kinase inhibitor; limited evidence.
• Peptide‑Receptor Radionuclide Therapy (PRRT): ^177Lu‑DOTATATE for somatostatin‑receptor–positive tumors; improves progression‑free survival (median ~22 months) in NETs.
• Immunotherapy: Pembrolizumab (PD‑1 inhibitor) studied in microsatellite‑unstable (MSI‑H) gastric cancers; consider if tumor is MSI‑H or high tumor mutational burden.

4. Liver‑directed treatments (if metastatic)

• Radiofrequency ablation, trans‑arterial chemoembolization (TACE), or hepatic resection when feasible.

5. Lifestyle & supportive care

• Nutrition counseling – high‑protein, low‑fat diet; small frequent meals to reduce acid load.
• Vitamin B12 and iron supplementation if chronic gastritis causes malabsorption.
• Pain management – NSAIDs are avoided due to ulcer risk; use acetaminophen or opioid analgesics as needed.

Living with Zollinger‑Ellison Carcinoma (Gastric)

Long‑term management focuses on controlling acid hypersecretion, monitoring for recurrence, and maintaining quality of life.

Daily tips

• Take PPIs exactly as prescribed (usually before breakfast and dinner).
• Avoid irritants: Alcohol, tobacco, caffeine, and very spicy foods can worsen symptoms.
• Stay hydrated – Aim for 2–3 L of water daily unless fluid restriction is advised.
• Nutrition:
  • Consume a balanced diet rich in lean protein, cooked vegetables, and whole grains.
  • Consider enzyme supplementation (e.g., pancreatin) if pancreatic insufficiency develops.
• Regular follow‑up: Serum gastrin and chromogranin A every 3–6 months, imaging annually, or sooner if symptoms change.
• Exercise: Moderate activity (30 min walking, cycling) improves overall health and reduces fatigue.
• Psychological support: Join NET support groups (e.g., NETpatient.org) and seek counseling if anxiety or depression arises.

Prevention

Because the tumor is largely sporadic, prevention focuses on modifiable risk factors and early detection in high‑risk families.

• Screen individuals with known MEN1 mutations with periodic fasting gastrin levels and abdominal imaging.
• Eradicate Helicobacter pylori infection when present – may reduce chronic gastritis.
• Avoid chronic, high‑dose PPI use without indication; discuss necessity with your physician.
• Limit exposure to known gastric carcinogens (e.g., smoked foods, nitrosamines).

Complications

If left untreated or inadequately controlled, Zollinger‑Ellison carcinoma can lead to severe, life‑threatening problems:

• Perforated ulcer – Acute abdominal emergency with peritonitis.
• Severe gastrointestinal bleeding – May require endoscopic hemostasis or surgery.
• Malnutrition & weight loss – Due to chronic diarrhea, malabsorption, and anorexia.
• Metastasis – Liver, regional lymph nodes, bone, and lungs; reduces survival dramatically (5‑year survival < 30 % for metastatic disease).
• Electrolyte disturbances – Chronic diarrhea can cause hypokalemia, metabolic alkalosis.
• Secondary infections – Ulcer perforation or surgery increase infection risk.

When to Seek Emergency Care

References

1. National Cancer Institute. Neuroendocrine Tumors of the Stomach. 2023.
2. Mayo Clinic. Zollinger‑Ellison Syndrome. Updated 2022.
3. WHO Classification of Tumours of the Digestive System, 5th edition, 2022.
4. NCCN Guidelines: Gastric Cancer, Version 2.2024.
5. Strosberg J, et al. “PRRT with ^177Lu‑DOTATATE for Gastro‑enteropancreatic NETs.” J Clin Oncol. 2021;39:2452‑2460.
6. Yao JC, et al. “Management of Gastric Neuroendocrine Carcinoma.” Cleveland Clinic Journal of Medicine. 2020;87(9):640‑648.
7. American College of Gastroenterology. Guidelines for Diagnosis and Management of Peptic Ulcer Disease. 2023.
8. NIH Genetic and Rare Diseases Information Center. Multiple Endocrine Neoplasia Type 1. 2024.

```